Clinical Trials Logo

Clostridium Infections clinical trials

View clinical trials related to Clostridium Infections.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT05256693 Not yet recruiting - Clinical trials for Stem Cell Transplant Complications

Prevention of C.Difficile Infections With Oral Vancomycine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

VANCALLO
Start date: March 2022
Phase: Phase 3
Study type: Interventional

Clostridium difficile (CD) infection are an important cause of morbi-mortality in patients undergoing allogeneic hematopoietic stem cell transplant (HSCT). The VANCALLO trial aims at evaluating oral vancomycine reducing the risk of CD infection relying on a placebo controlled 1:1 randomized design, including one interim analysis.

NCT ID: NCT04960306 Not yet recruiting - Clinical trials for Clostridium Difficile Infection

Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection

FILTRATE
Start date: November 1, 2023
Phase: Phase 3
Study type: Interventional

Clostridioides difficile infection (CDI) is one of the most common hospital-acquired infectious diseases with a high mortality rate (6-30%). The treatment of CDI, especially the recurrent form of the disease is still considered a challenge. The FILTRATE randomized controlled trial aims to investigate the safety and efficacy of fecal filtrate transplantation in the treatment of recurrent CDI and compare it with conventional fecal microbiota transplantation (FMT).

NCT ID: NCT04567134 Not yet recruiting - Clinical trials for Clostridium Difficile Infection

Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea

Start date: October 1, 2020
Phase:
Study type: Observational

Our objective of this study is to derive a real incidence of CDI in tertiary hospitals located through Korean peninsula. In order to get a close value to the truth, the study is planned to co-perform with a national study which was proposed in evaluation process to include more hospitals. Along with the incidence of CDI, clinical characteristics and outcome of CDI will be examined and microbiologic characteristics of C. difficile isolates from CDI patients are studied.

NCT ID: NCT04415918 Not yet recruiting - Clinical trials for Clostridium Difficile Infection Recurrence

Bezlotoxumab Efficacy and Tolerability in Cancer Patient

Start date: July 1, 2020
Phase: Phase 4
Study type: Interventional

Investigation of efficacy and tolerability of bezlotoxumab in patients with cancer diagnosis in terms of preventing CDI recurrence.

NCT ID: NCT04259931 Not yet recruiting - Clinical trials for Clostridium Difficile Infection

PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMA

Start date: March 1, 2020
Phase:
Study type: Observational

A higher frequency of recurrences in the University Hospital of Cabueñes (HUCAB) than in other hospitals in our area, including Central University Hospital of Asturias (HUCA) has been found. This increase does not seem to be related to underlying diseases, age, sex or predisposing factors classically described in this type of infection. This high rate of recurrence, together with the absence of response to all conventionally used antibiotic treatments, has important repercussions in the morbidity and mortality of patients, in the ecology of the hospital due to the risk of transmission of a strain of major severity and in the high costs associated with an increase in the hospitalization days of these patients, as well as in an eventual transfer of these to other structures specialized in fecal transplantation. Two hypotheses are proposed to explain the higher frequency reported: Hypothesis 1. There are alterations of the microbiome in patients with severe recurrences that favor the appearance of these. Hypothesis 2. The circulating strain in the hospital has intrinsic characteristics that make it more virulent, such as the presence of virulence or multiresistance factors. For this reason we design a descriptive, prospective multicentric study that will include all patients older than 18 years diagnosed with C difficile infection at the Central University Hospital of Asturias and the University Hospital of Cabueñes during the year 2020-2021